XFOR, US98420X2027

X4 sets October 29 investor day. MarketBeat cites USD 11.25 for X4 Pharmaceuticals stock

Published on 10/16/2026 at 03:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 29 event covers Phase 3 4WARD and a planned Phase 2 study. A USD 11.25 average target is cited for X4 Pharmaceuticals stock.

Upcoming clinical milestones

X4 Pharmaceuticals announced its October 29, 2026 Investor Day on October 9, 2026.
The company secured a USD 150.0 million financing facility on October 8, 2026.
X4 Pharmaceuticals had a USD 261.7 million market capitalization as of October 15, 2026.

XFOR, US98420X2027, Illustration mit AI erstellt.

X4 Pharmaceuticals (ISIN US98420X2027) scheduled a virtual Investor Day for October 29, 2026, with discussions on mavorixafor, Phase 3 4WARD and a planned Phase 2 study. GlobeNewswire reported the announcement on October 9, 2026. The event gives investors a dated update on the companys next clinical milestones.

Financing supports clinical plans

The backdrop is a new senior secured term loan facility of up to USD 150.0 million. An initial USD 80.0 million tranche funded on October 7, 2026, while as much as USD 70.0 million may become available subject to lender approval, according to StockTitan. The agreement also provides for a conversion option covering up to USD 15.0 million of principal at USD 3.2341 per share.

Three dates define the setup

On October 1, 2026, X4 announced inducement options covering 80,000 shares at USD 2.90 per share. On October 8, 2026, it announced the USD 150.0 million debt facility. On October 9, 2026, it scheduled the Investor Day for October 29, 2026. These dated steps connect employee hiring, financing and clinical communication.

Upcoming dates for investors

The next scheduled event is the Investor Day on October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET. X4 also expects to complete enrollment in the Phase 3 4WARD trial by year-end 2026 and report topline results in the first half of 2028, according to StockTitan.

What does the financing mean for cash?

The second-quarter 2026 figures show USD 8.806 million in revenue, a net loss of USD 16.157 million and USD 195.095 million in cash and cash equivalents. The company also used USD 20.788 million in operating cash during the quarter, according to MarketBeat. The financing therefore adds borrowing capacity while clinical spending remains material.

Clinical milestones remain central

X4 is developing mavorixafor for rare hematology diseases and is evaluating it in chronic neutropenic disorders. Its market capitalization was USD 261.7 million as of October 15, 2026, while MarketBeat cited a USD 11.25 average 12-month target from six analysts on October 8, 2026. The Investor Day may provide further detail on the trial path and potential commercial opportunity.